Caitong International Asset Management Co., LTD Allogene Therapeutics, Inc. Transaction History
Caitong International Asset Management Co., LTD
- $134 Billion
- Q1 2025
A detailed history of Caitong International Asset Management Co., LTD transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Caitong International Asset Management Co., LTD holds 624 shares of ALLO stock, worth $736. This represents 0.0% of its overall portfolio holdings.
Number of Shares
624
Previous 150
316.0%
Holding current value
$736
Previous $320,000
184.69%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ALLO
# of Institutions
177Shares Held
165MCall Options Held
202KPut Options Held
76.6K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$22.1 Million0.84% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$19.4 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA12.3MShares$14.5 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR11.1MShares$13 Million5.97% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y910.4MShares$12.3 Million1.06% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $170M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...